Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

OBJECTIVE: Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This phase 2b, adaptive, dose-range finding study aimed to assess the efficacy and safety of multiple doses of elinzanetant (NT-814), a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, James A., Anderson, Richard A., Ballantyne, Elizabeth, Bolognese, James, Caetano, Cecilia, Joffe, Hadine, Kerr, Mary, Panay, Nick, Seitz, Christian, Seymore, Susan, Trower, Mike, Zuurman, Lineke, Pawsey, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970022/
https://www.ncbi.nlm.nih.gov/pubmed/36720081
http://dx.doi.org/10.1097/GME.0000000000002138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970022/
https://www.ncbi.nlm.nih.gov/pubmed/36720081
http://dx.doi.org/10.1097/GME.0000000000002138

Ejemplares similares